Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.56
CORT's Cash to Debt is ranked lower than
68% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. CORT: 2.56 )
Ranked among companies with meaningful Cash to Debt only.
CORT' s Cash to Debt Range Over the Past 10 Years
Min: 0.72  Med: 1135.78 Max: No Debt
Current: 2.56
Equity to Asset 0.50
CORT's Equity to Asset is ranked lower than
70% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CORT: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
CORT' s Equity to Asset Range Over the Past 10 Years
Min: -0.1  Med: 0.51 Max: 0.89
Current: 0.5
-0.1
0.89
Interest Coverage 2.94
CORT's Interest Coverage is ranked lower than
93% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CORT: 2.94 )
Ranked among companies with meaningful Interest Coverage only.
CORT' s Interest Coverage Range Over the Past 10 Years
Min: 2.94  Med: N/A Max: No Debt
Current: 2.94
F-Score: 7
Z-Score: 11.59
M-Score: -2.97
WACC vs ROIC
12.26%
136.64%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 9.41
CORT's Operating margin (%) is ranked higher than
79% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. CORT: 9.41 )
Ranked among companies with meaningful Operating margin (%) only.
CORT' s Operating margin (%) Range Over the Past 10 Years
Min: -69827.59  Med: -1818.64 Max: 9.41
Current: 9.41
-69827.59
9.41
Net-margin (%) 6.21
CORT's Net-margin (%) is ranked higher than
77% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. CORT: 6.21 )
Ranked among companies with meaningful Net-margin (%) only.
CORT' s Net-margin (%) Range Over the Past 10 Years
Min: -69537.93  Med: -1775.79 Max: 6.21
Current: 6.21
-69537.93
6.21
ROE (%) 20.64
CORT's ROE (%) is ranked higher than
93% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. CORT: 20.64 )
Ranked among companies with meaningful ROE (%) only.
CORT' s ROE (%) Range Over the Past 10 Years
Min: -356.04  Med: -113.3 Max: 20.64
Current: 20.64
-356.04
20.64
ROA (%) 8.25
CORT's ROA (%) is ranked higher than
89% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. CORT: 8.25 )
Ranked among companies with meaningful ROA (%) only.
CORT' s ROA (%) Range Over the Past 10 Years
Min: -124.18  Med: -87.4 Max: 8.25
Current: 8.25
-124.18
8.25
ROC (Joel Greenblatt) (%) 265.76
CORT's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. CORT: 265.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CORT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -370585.71  Med: -49033.54 Max: 265.76
Current: 265.76
-370585.71
265.76
Revenue Growth (3Y)(%) 135.50
CORT's Revenue Growth (3Y)(%) is ranked higher than
95% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. CORT: 135.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CORT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 230.2
Current: 135.5
0
230.2
EBITDA Growth (3Y)(%) -57.00
CORT's EBITDA Growth (3Y)(%) is ranked lower than
95% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. CORT: -57.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CORT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -16.85 Max: 3
Current: -57
0
3
EPS Growth (3Y)(%) -47.30
CORT's EPS Growth (3Y)(%) is ranked lower than
88% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. CORT: -47.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CORT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -47.3  Med: -11.35 Max: 6.6
Current: -47.3
-47.3
6.6
» CORT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

CORT Guru Trades in Q4 2015

Paul Tudor Jones 27,099 sh (+27.35%)
Jim Simons 460,400 sh (+1.81%)
Joel Greenblatt 17,347 sh (+0.73%)
First Eagle Investment 300,000 sh (unchged)
David Swensen Sold Out
» More
Q1 2016

CORT Guru Trades in Q1 2016

First Eagle Investment 395,670 sh (+31.89%)
Paul Tudor Jones 28,799 sh (+6.27%)
Joel Greenblatt Sold Out
Jim Simons 191,400 sh (-58.43%)
» More
Q2 2016

CORT Guru Trades in Q2 2016

Joel Greenblatt 15,024 sh (New)
Jim Simons 310,600 sh (+62.28%)
Paul Tudor Jones 28,449 sh (-1.22%)
First Eagle Investment 223,935 sh (-43.40%)
» More
Q3 2016

CORT Guru Trades in Q3 2016

Jim Simons 560,000 sh (+80.30%)
Joel Greenblatt 20,908 sh (+39.16%)
Paul Tudor Jones 23,564 sh (-17.17%)
First Eagle Investment 125,000 sh (-44.18%)
» More
» Details

Insider Trades

Latest Guru Trades with CORT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BPMC, NAS:AIMT, NAS:MGNX, NAS:ACOR, NAS:FWP, NAS:BGNE, OTCPK:PFSCF, NAS:PTLA, NAS:ZIOP, NAS:INSY, NAS:INSM, NAS:ADRO, NAS:WVE, NAS:AMRN, NAS:XNCR, NAS:INVA, NAS:RGEN, NAS:AMAG, OTCPK:SXMDF, NAS:DERM » details
Traded in other countries:HTD.Germany,
Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders associated with thesteroid hormone cortisol.

Corcept Therapeutics Inc was incorporated in the State of Delaware on May 13, 1998. The Company is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric and oncologic disorders. The Company focuses on disorders associated with the steroid hormone cortisol. The company focuses on commercializing Korlym 300 mg Tablet, a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It is also conducting a Phase III clinical study for mifepristone, the active ingredient in Korlym, for the treatment of psychotic depression; and developing CORT 108297, a novel glucocorticoid receptor II antagonist in Phase 1b/2a clinical trial. The Company has research and development agreement with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. as well as has a patent license from Stanford University for developing mifepristone.

Ratios

vs
industry
vs
history
P/E(ttm) 208.29
CORT's P/E(ttm) is ranked lower than
94% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. CORT: 208.29 )
Ranked among companies with meaningful P/E(ttm) only.
CORT' s P/E(ttm) Range Over the Past 10 Years
Min: 132.75  Med: 243 Max: 601
Current: 208.29
132.75
601
PE(NRI) 208.29
CORT's PE(NRI) is ranked lower than
94% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. CORT: 208.29 )
Ranked among companies with meaningful PE(NRI) only.
CORT' s PE(NRI) Range Over the Past 10 Years
Min: 132.75  Med: 243 Max: 601
Current: 208.29
132.75
601
Price/Owner Earnings (ttm) 106.81
CORT's Price/Owner Earnings (ttm) is ranked lower than
82% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 28.19 vs. CORT: 106.81 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
CORT' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 68.08  Med: 124.62 Max: 667.78
Current: 106.81
68.08
667.78
P/B 29.57
CORT's P/B is ranked lower than
95% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. CORT: 29.57 )
Ranked among companies with meaningful P/B only.
CORT' s P/B Range Over the Past 10 Years
Min: 1.82  Med: 11.44 Max: 86.18
Current: 29.57
1.82
86.18
P/S 12.97
CORT's P/S is ranked lower than
54% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. CORT: 12.97 )
Ranked among companies with meaningful P/S only.
CORT' s P/S Range Over the Past 10 Years
Min: 7.18  Med: 175.17 Max: 1990
Current: 12.97
7.18
1990
PFCF 69.44
CORT's PFCF is ranked lower than
79% of the 123 Companies
in the Global Biotechnology industry.

( Industry Median: 24.25 vs. CORT: 69.44 )
Ranked among companies with meaningful PFCF only.
CORT' s PFCF Range Over the Past 10 Years
Min: 44.25  Med: 128.75 Max: 180
Current: 69.44
44.25
180
POCF 52.06
CORT's POCF is ranked lower than
78% of the 186 Companies
in the Global Biotechnology industry.

( Industry Median: 19.60 vs. CORT: 52.06 )
Ranked among companies with meaningful POCF only.
CORT' s POCF Range Over the Past 10 Years
Min: 33.19  Med: 62.89 Max: 182.41
Current: 52.06
33.19
182.41
EV-to-EBIT 131.31
CORT's EV-to-EBIT is ranked lower than
94% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. CORT: 131.31 )
Ranked among companies with meaningful EV-to-EBIT only.
CORT' s EV-to-EBIT Range Over the Past 10 Years
Min: -160.5  Med: -5.8 Max: 488.9
Current: 131.31
-160.5
488.9
EV-to-EBITDA 129.40
CORT's EV-to-EBITDA is ranked lower than
92% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. CORT: 129.40 )
Ranked among companies with meaningful EV-to-EBITDA only.
CORT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -168  Med: -5.8 Max: 436.4
Current: 129.4
-168
436.4
Current Ratio 1.89
CORT's Current Ratio is ranked lower than
76% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. CORT: 1.89 )
Ranked among companies with meaningful Current Ratio only.
CORT' s Current Ratio Range Over the Past 10 Years
Min: 1.89  Med: 7.21 Max: 37.77
Current: 1.89
1.89
37.77
Quick Ratio 1.81
CORT's Quick Ratio is ranked lower than
73% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. CORT: 1.81 )
Ranked among companies with meaningful Quick Ratio only.
CORT' s Quick Ratio Range Over the Past 10 Years
Min: 1.81  Med: 7.21 Max: 37.77
Current: 1.81
1.81
37.77
Days Inventory 378.89
CORT's Days Inventory is ranked lower than
88% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. CORT: 378.89 )
Ranked among companies with meaningful Days Inventory only.
CORT' s Days Inventory Range Over the Past 10 Years
Min: 378.89  Med: 1093.61 Max: 2487.36
Current: 378.89
378.89
2487.36
Days Sales Outstanding 41.48
CORT's Days Sales Outstanding is ranked higher than
68% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. CORT: 41.48 )
Ranked among companies with meaningful Days Sales Outstanding only.
CORT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.48  Med: 48.08 Max: 61.48
Current: 41.48
41.48
61.48
Days Payable 845.13
CORT's Days Payable is ranked higher than
99% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. CORT: 845.13 )
Ranked among companies with meaningful Days Payable only.
CORT' s Days Payable Range Over the Past 10 Years
Min: 355.35  Med: 3428.94 Max: 15257.8
Current: 845.13
355.35
15257.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.20
CORT's 3-Year Average Share Buyback Ratio is ranked higher than
78% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. CORT: -3.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CORT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -61.6  Med: -21.3 Max: -3.2
Current: -3.2
-61.6
-3.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 55.20
CORT's Price/Net Cash is ranked lower than
93% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. CORT: 55.20 )
Ranked among companies with meaningful Price/Net Cash only.
CORT' s Price/Net Cash Range Over the Past 10 Years
Min: 2.5  Med: 6.36 Max: 376
Current: 55.2
2.5
376
Price/Net Current Asset Value 33.12
CORT's Price/Net Current Asset Value is ranked lower than
90% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. CORT: 33.12 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CORT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.43  Med: 6.34 Max: 93.33
Current: 33.12
2.43
93.33
Price/Tangible Book 29.57
CORT's Price/Tangible Book is ranked lower than
94% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. CORT: 29.57 )
Ranked among companies with meaningful Price/Tangible Book only.
CORT' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.31  Med: 6.3 Max: 82.35
Current: 29.57
2.31
82.35
Price/Median PS Value 0.07
CORT's Price/Median PS Value is ranked higher than
98% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. CORT: 0.07 )
Ranked among companies with meaningful Price/Median PS Value only.
CORT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.05  Med: 0.35 Max: 7.17
Current: 0.07
0.05
7.17
Price/Graham Number 16.56
CORT's Price/Graham Number is ranked lower than
96% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 2.38 vs. CORT: 16.56 )
Ranked among companies with meaningful Price/Graham Number only.
CORT' s Price/Graham Number Range Over the Past 10 Years
Min: 13  Med: 18.37 Max: 23.74
Current: 16.56
13
23.74
Earnings Yield (Greenblatt) (%) 0.75
CORT's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. CORT: 0.75 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CORT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 0.6 Max: 1.2
Current: 0.75
0.2
1.2

More Statistics

Revenue (TTM) (Mil) $72.48
EPS (TTM) $ 0.04
Beta1.33
Short Percentage of Float7.29%
52-Week Range $3.22 - 10.00
Shares Outstanding (Mil)111.03
» More Articles for CORT

Headlines

Articles On GuruFocus.com
David Swensen Bets on Antero Resources Mar 10 2016 
Two Stocks for the Value Investor and GAARP Enthusiast Jun 07 2014 
Corcept Therapeutics Inc. Reports Operating Results (10-K/A) Aug 19 2010 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Aug 16 2010 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Nov 12 2009 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Aug 11 2009 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) May 13 2009 

More From Other Websites
Corcept Therapeutics Announces Encouraging Results of Phase 1/2 Trial of Mifepristone Plus Eribulin... Dec 10 2016
Corcept (CORT) Looks Good: Stock Jumps 6.5% in Session Nov 11 2016
CORCEPT THERAPEUTICS INC Financials Nov 05 2016
Corcept (CORT) Beats on Q3 Earnings, Lifts Sales Guidance Nov 02 2016
CORCEPT THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report Nov 02 2016
Edited Transcript of CORT earnings conference call or presentation 1-Nov-16 9:00pm GMT Nov 02 2016
Corcept beats 3Q profit forecasts Nov 01 2016
Corcept beats 3Q profit forecasts Nov 01 2016
Corcept Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update Nov 01 2016
CORCEPT THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure Nov 01 2016
Corcept Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update Nov 01 2016
Q3 2016 Corcept Therapeutics Inc Earnings Release - After Market Close Nov 01 2016
Corcept Therapeutics to Announce Third Quarter 2016 Financial Results and Corporate Update and Host... Oct 26 2016
Corcept Therapeutics to Announce Third Quarter 2016 Financial Results and Corporate Update and Host... Oct 26 2016
Top 3 Growth Stocks Under $10 Sep 29 2016
Ionis/Biogen Complete Nusinersen NDA Submission in U.S. Sep 27 2016
PAREXEL International (PRXL) Set to Acquire ExecuPharm Sep 27 2016
Array (ARRY) Hits 52-Week High on Positive Phase III Data Sep 27 2016
Novartis Ilaris Approved for Extended Use in Periodic Fever Sep 26 2016
Glaxo/J&J File BLA for Rheumatoid Arthritis Drug in the U.S. Sep 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)